UroGen Pharma Ltd. (URGN)
NASDAQ: URGN
· Real-Time Price · USD
7.38
2.24 (43.58%)
At close: Jun 06, 2025, 3:59 PM
7.55
2.37%
After-hours: Jun 06, 2025, 05:59 PM EDT
UroGen Pharma Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Jelmyto Revenue | 90.4M | 82.71M | 64.36M | 48.04M |
| Jelmyto Revenue Growth | +9.29% | +28.52% | +33.96% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 34.97M | 34.86M | 28.94M | 30.06M | 27.3M | 24.55M | 21.75M | 22.49M | 24.47M | 21.63M | 19.07M | 20.83M | 21.3M | 21.42M | 21.62M | 22.3M | 22.19M | 22.16M | 22.07M | 24.02M | 21.97M | 19.75M | 13.97M | 13.78M | 12.71M | 12.55M | 10.74M | 10.21M | 6.07M | 3.44M | 2.2M | 2.3M | 875K | 1.23M | 3.24M | 1.04M | 907K | 886K | 194K |
| Selling, General, and Administrative Revenue Growth | +0.31% | +20.45% | -3.71% | +10.10% | +11.19% | +12.85% | -3.29% | -8.09% | +13.13% | +13.44% | -8.46% | -2.19% | -0.55% | -0.95% | -3.05% | +0.52% | +0.12% | +0.44% | -8.13% | +9.31% | +11.28% | +41.32% | +1.43% | +8.40% | +1.23% | +16.84% | +5.25% | +68.18% | +76.58% | +56.30% | -4.39% | +162.86% | -28.80% | -62.03% | +210.06% | +15.10% | +2.37% | +356.70% | n/a |
| Research and Development Revenue | 19.87M | 14.89M | 11.36M | 15.4M | 15.49M | 11.3M | 10.23M | 11.58M | 12.5M | 14.48M | 13.09M | 12.64M | 12.7M | 13.08M | 11.92M | 12.12M | 10.51M | 12.4M | 10.21M | 8.11M | 16.59M | 20.09M | 9.48M | 10M | 9.73M | 11.46M | 9.57M | 8.27M | 7.62M | 6.76M | 5.62M | 3.65M | 2.66M | 2.37M | 2.87M | 2.35M | 2.81M | 7.24M | 1.84M |
| Research and Development Revenue Growth | +33.42% | +31.17% | -26.28% | -0.59% | +37.09% | +10.48% | -11.69% | -7.31% | -13.67% | +10.57% | +3.58% | -0.44% | -2.95% | +9.72% | -1.66% | +15.32% | -15.25% | +21.49% | +25.97% | -51.13% | -17.45% | +111.94% | -5.15% | +2.78% | -15.17% | +19.75% | +15.73% | +8.54% | +12.73% | +20.28% | +53.96% | +37.05% | +12.31% | -17.44% | +22.20% | -16.22% | -61.23% | +293.37% | n/a |